Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA Gives Directions On Navigating Generic 180-Day Exclusivity Maze

Jan 26 2017

• By Brenda Sandburg

FDA entrance sign 2016

Related Content

FDA Explains How It Counts To 30 Months

Feb 02 2015

Teva Loses 180-Day Exclusivity For Generic Actonel As FDA Stands Firm On Review Delays

Sep 03 2014

Biosimilar Guidances Could Be Left Out In Cold By White House Regulatory Freeze

Jan 26 2017

FDA Wrangles With Generic Exclusivity, Looks To Courts For Direction

Oct 18 2010

Par Fights FDA Forfeiture Of Generic Colcrys Exclusivity

Oct 03 2016

FDA Hit With Slew Of Suits As Firms Fight For Market Advantage

Nov 26 2012

Related Companies

Par Pharmaceutical Companies Inc.

Endo, Inc.

Takeda Pharmaceutical Co. Ltd.

Novartis AG

Ranbaxy Laboratories Limited

AstraZeneca PLC

Teva Pharmaceutical Industries Ltd.

Allergan plc

Teva Pharmaceutical Industries Ltd.

Additional Topics

Regulation FDA Legal Issues Intellectual Property Generic Drugs BioPharmaceutical

More from US FDA

More from Agency Leadership

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window